Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; Innovative Genomics Institute, University of California, Berkeley, Berkeley, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States; Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, The Bronx, United States
Yogendra Verma
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Khaja Mohieddin Syed
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States
Gabriella R Pangilinan
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Luke A Gilbert
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, United States; Department of Urology, University of California, San Francisco, San Francisco, United States; Arc Institute, Palo Alto, United States
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States; Chan Zuckerberg Biohub, San Francisco, United States; Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, United States
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States
Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, United States; Innovative Genomics Institute, University of California, Berkeley, Berkeley, United States; Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States; Chan Zuckerberg Biohub, San Francisco, United States
Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, United States; Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, The Bronx, United States; Department of Genetics, Albert Einstein College of Medicine, The Bronx, United States; Ruth L. and David S. Gottesman Institute for Stem Cell and Regenerative Medicine Research, Albert Einstein College of Medicine, The Bronx, United States
The recent development of prime editing (PE) genome engineering technologies has the potential to significantly simplify the generation of human pluripotent stem cell (hPSC)-based disease models. PE is a multicomponent editing system that uses a Cas9-nickase fused to a reverse transcriptase (nCas9-RT) and an extended PE guide RNA (pegRNA). Once reverse transcribed, the pegRNA extension functions as a repair template to introduce precise designer mutations at the target site. Here, we systematically compared the editing efficiencies of PE to conventional gene editing methods in hPSCs. This analysis revealed that PE is overall more efficient and precise than homology-directed repair of site-specific nuclease-induced double-strand breaks. Specifically, PE is more effective in generating heterozygous editing events to create autosomal dominant disease-associated mutations. By stably integrating the nCas9-RT into hPSCs we achieved editing efficiencies equal to those reported for cancer cells, suggesting that the expression of the PE components, rather than cell-intrinsic features, limit PE in hPSCs. To improve the efficiency of PE in hPSCs, we optimized the delivery modalities for the PE components. Delivery of the nCas9-RT as mRNA combined with synthetically generated, chemically-modified pegRNAs and nicking guide RNAs improved editing efficiencies up to 13-fold compared with transfecting the PE components as plasmids or ribonucleoprotein particles. Finally, we demonstrated that this mRNA-based delivery approach can be used repeatedly to yield editing efficiencies exceeding 60% and to correct or introduce familial mutations causing Parkinson’s disease in hPSCs.